Lung function abnormalities in smokers with ischemic heart disease

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 5, 2016, Pages 568-576

  Franssen, Frits M E ^a   Soriano, Joan B ^b   Roche, Nicolas ^c   Bloomfield, Paul H ^d   Brusselle, Guy ^e   Fabbri, Leonardo M ^f   García Rio, Francisco ^g   Kearney, Mark T ^h   Kwon, Namhee ^d   Lundbäck, Bo ⁱ   Rabe, Klaus F ^j   Raillard, Alice ^k,m   Muellerova, Hana ^d   Cockcroft, John R ^l  

^a Centre of Expertise for Chronic Organ Failure   (Netherlands)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c université Paris Cité   (France)

^d GLAXOSMITHKLINE   (United Kingdom)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j UNIVERSITY OF KIEL   (Germany)

^k Cardiff University ^*  (France)

^l CARDIFF UNIVERSITY   (United Kingdom)

^m SANOFI PASTEUR   (France)

more..

Author keywords

Airflow limitation; Chronic obstructive pulmonary disease; Ischemic heart disease; Prevalence; Smoking

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; BRONCHODILATING AGENT;

AGE; AGED; ARTICLE; BODY MASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EMPHYSEMA; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRAMINGHAM RISK SCORE; HUMAN; ISCHEMIC HEART DISEASE; LUNG FUNCTION; MALE; OUTPATIENT; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; SMOKING; SPIROMETRY; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; COMORBIDITY; COMPLICATION; DRUG EFFECTS; LUNG; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTOR; STATISTICAL MODEL;

AGED; ANALYSIS OF VARIANCE; BRONCHODILATOR AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL ISCHEMIA; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK FACTORS; SMOKING; SPIROMETRY;

EID: 84988835518     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201512-2480OC     Document Type: Article

References (47)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385: 117-171.
2. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, et al.; Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
3. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-365.
4. Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, Hattori N, Hara H, Kohno N. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009;179: 35-40.
5. Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest 2014;44:93-102.
6. Soriano JB, Rigo F, Guerrero D, Yañez A, Forteza JF, Frontera G, Togores B, Agustí A. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010;137: 333-340.
7. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750.
8. Onishi K, Yoshimoto D, Hagan GW, Jones PW. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis 2014;9:563-568.
9. Wada H, Nakano Y, Nagao T, Osawa M, Yamada H, Sakaguchi C, Matsumoto T, Tsutamoto T, Ito M, Horie M. Detection and prevalence of chronic obstructive pulmonary disease in a cardiovascular clinic: evaluation using a hand held FEV1/FEV6 meter and questionnaire. Respirology 2010;15:1252-1258.
10. Bé rard E, Bongard V, Roche N, Perez T, Brouquières D, Taraszkiewicz D, Fievez S, Denis F, Escamilla R, Ferrières J. Undiagnosed airflow limitation in patients at cardiovascular risk. Arch Cardiovasc Dis 2011;104:619-626.
11. Soriano JB, Roche N, Cockcroft JR, Rabe KF, Kearney M, Brusselle G, et al. Prevalence and under-diagnosis of airflow limitation and other lung function abnormalities in patients with ischaemic heart disease: an interim analysis of the ALICE study. Eur Respir J 2012;40(Suppl 56):P450.
12. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Physicians; American Association for Thoracic Surgery; Preventive Cardiovascular Nurses Association; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44-e164.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26:319-338.
14. Hankinson JL, Eschenbacher B, Townsend M, Stocks J, Quanjer PH. Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test. Eur Respir J 2015; 45:1283-1292.
15. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-586.
16. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978;118:1-120.
17. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 2002;18:371-379.
18. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation 1994;90:644-645.
19. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
20. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753.
21. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701.
22. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012.
23. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-654.
24. Währborg P, Emanuelsson H. The cardiac health profile: content, reliability and validity of a new disease-specific quality of life questionnaire. Coron Artery Dis 1996;7:823-829.
25. Burdine JN, Felix MR, Abel AL, Wiltraut CJ, Musselman YJ. The SF-12 as a population health measure: an exploratory examination of potential for application. Health Serv Res 2000;35:885-904.
26. Almagro P, Lapuente A, Pareja J, Yun S, Garcia ME, Padilla F, Heredia JLI, De la Sierra A, Soriano JB. Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis 2015;10:1353-1361.
27. Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, Burney P, Miravitlles M, García-Rio F, Akbari K, et al.; BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team, and the PREPOCOL Study Group; BOLD Collaborative Research Group the EPI-SCAN Team the PLATINO Team and the PREPOCOL Study Group. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015;148:971-985.
28. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, Hartge P, Gapstur SM. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013;368:351-364.
29. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-2260.
30. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation 2007;116:2110-2118.
31. Van Remoortel H, Hornikx M, Langer D, Burtin C, Everaerts S, Verhamme P, Boonen S, Gosselink R, Decramer M, Troosters T, et al. Risk factors and comorbidities in the preclinical stages of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:30-38.
32. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a populationbased cohort study. Am J Respir Crit Care Med 2007;175:458-463.
33. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur Respir J 2015;45:790-806.
34. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Eur Respir J 2014;44:1332-1352.
35. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-715, discussion 715-716.
36. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-664.
37. Lahousse L, Niemeijer MN, van den Berg ME, Rijnbeek PR, Joos GF, Hofman A, Franco OH, Deckers JW, Eijgelsheim M, Stricker BH, et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J 2015;36: 1754-1761.
38. Vallerio P, Ferrari M, Rainer S, Albiero A, Frattat Pasini A, Cominacini L. Cardiovascular function and comorbidities in elderly subjects with COPD. Eur Heart J 2013;34(Suppl 1):P5168.
39. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:797-799.
40. Enright PL, Kronmal RA, Smith VE, Gardin JM, Schenker MB, Manolio TA. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study. Chest 1995;107:28-35.
41. Vanfleteren LE, Lamprecht B, Studnicka M, Kaiser B, Gnatiuc L, Burney P, Wouters EF, Franssen FM. Body mass index and chronic airflow limitation in a worldwide population-based study. Chron Respir Dis 2016;13:90-101.
42. Stefan MS, Bannuru RR, Lessard D, Gore JM, Lindenauer PK, Goldberg RJ. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest 2012;141: 1441-1448.
43. Hadi HA, Zubaid M, Al Mahmeed W, El-Menyar AA, Ridha M, Alsheikh-Ali AA, Singh R, Assad N, Al Habib K, Al Suwaidi J. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol 2010;33:228-235.
44. Rothnie KJ, Yan R, Smeeth L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015;5:e007824.
45. Aaron SD, Dales RE, Cardinal P. How accurate is spirometry at predicting restrictive pulmonary impairment? Chest 1999;115: 869-873.
46. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, et al.; Writing Group Members; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
47. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J 2011;38:29-35.